# Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

> **NCT00747799** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 54 (actual)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **DRUG:** Sorafenib plus Cisplatin and 5-fluorouracil

## Key facts

- **NCT ID:** NCT00747799
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-05
- **Final completion:** 2011-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747799, "Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00747799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*